{
    "clinical_study": {
        "@rank": "68968", 
        "arm_group": {
            "arm_group_label": "Patients with cytopenia after allo-HSCT", 
            "arm_group_type": "Experimental", 
            "description": "Patients with cytopenia after allo-HSCT"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of the sequential infusion\n      of allogeneic mesenchymal stem cells (MSC), expanded \"in vitro\" with platelet lysate without\n      addition of animal products in the treatment of patients undergoing allo-HSCT who developed\n      one or more cytopenias."
        }, 
        "brief_title": "Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro", 
        "condition": "Cytopenia", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with hematologic malignancies who have been subjected to allo-HSCT and that\n             are diagnosed with one or more peripheral cytopenias with complete chimerism in bone\n             marrow (determined by molecular-STR-studies). They may include:\n\n               1. Patients who have received as a source of cells MO or SP\n\n               2. Patients who have received cells from a related donor or unrelated HLA-matched\n\n               3. Patients transplanted with myeloablative or non-myeloablative conditioning\n\n          -  Adequate cardiac function assessed from a clinical point of view by the researcher,\n             with no history of ischemic heart disease (angina or myocardial infarction) in the\n             previous 6 months.\n\n          -  Adequate pulmonary function assessed clinically without evidence of severe\n             obstructive or restrictive lung disease.\n\n          -  Patients between 18 and 70 years\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  Patients whose haemopathy has not been controlled by the transplantation or is in\n             progress at the time of treatment.\n\n          -  Patients who do not have complete chimerism in bone marrow (performed within 28 days\n             prior to baseline by molecular study -STR-).\n\n          -  Patients with thrombotic microangiopathy.\n\n          -  Patients with post-transplant cytopenias with toxic origin in relation to antiviral\n             treatment (eg ganciclovir, valganciclovir) without concomitant graft against host\n             disease.\n\n          -  Patients with bacterial, viral or fungal infection that is not being controlled with\n             proper treatment.\n\n          -  Patients with a history of ischemic heart disease (angina or myocardial infarction)\n             in the previous 6 months, and those considered by the investigator does not have\n             adequate cardiac function, evaluated from a clinical point of view.\n\n          -  Patients with poor lung function, evaluated clinically, according to the researcher.\n\n          -  Patients who, in the opinion of the investigator, are not on a good position to\n             tolerate treatment.\n\n          -  Patients who do not have the required donor.\n\n          -  Women pregnant or at risk of pregnancy by contraceptive measures inadequate.\n\n          -  Patients <18 or > 70 years.\n\n          -  Patients who did not sign the informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104440", 
            "org_study_id": "CSM/CIT", 
            "secondary_id": "2013-000534-35"
        }, 
        "intervention": {
            "arm_group_label": "Patients with cytopenia after allo-HSCT", 
            "intervention_name": "Sequential infusion of allogeneic mesenchymal stem cells expanded \"in vitro\"", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Cytopenia", 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "contact": {
                "email": "ferminsg@usal.es", 
                "last_name": "Ferm\u00edn S\u00e1nchez-Guijo Mart\u00edn, Ph.D", 
                "phone": "+34923294624"
            }, 
            "facility": {
                "address": {
                    "city": "Salamanca", 
                    "country": "Spain", 
                    "state": "Salamanca/Castilla Le\u00f3n", 
                    "zip": "37007"
                }, 
                "name": "University Clinical Hospital of Salamanca"
            }, 
            "investigator": {
                "last_name": "Ferm\u00edn S\u00e1nchez-Guijo Mart\u00edn, Ph.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "overall_official": [
            {
                "affiliation": "University Clinical Hospital of Salamanca", 
                "last_name": "Ferm\u00edn S\u00e1nchez-Guijo Mart\u00edn, Ph.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Clinic of Navarra", 
                "last_name": "Jos\u00e9 Rif\u00f3n Roca, Ph.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Virgen del Roc\u00edo", 
                "last_name": "Jos\u00e9 A P\u00e9rez Sim\u00f3n, Ph.D", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All the adverse effects that may arise and possible toxicities (WHO grade) after infusion of the cells were collected.", 
            "measure": "Adverse effects at the time of infusion and infections after infusion of MSC", 
            "safety_issue": "Yes", 
            "time_frame": "During the period of infusion of the cells into the patient (an average of one hour)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104440"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The efficiency is measured by the recovery of cytopenia after administration of MSC (depending on the original cytopenia) and may be of two types:\nComplete response:\nHb> 10 g / dL\nNeutrophils> 1500 Million / L\nPlatelets> 100.000 Million / L\nMaintained at least 7 days\nPartial response:\nHb> 8 and <10 g / dL\nNeutrophils> 1000 and <1500 Million / L\nPlatelets> 50000 and <100.000 Million / L\nMaintained at least 7 days", 
            "measure": "Mesenchymal cell efficiency in recovering cytopenia", 
            "safety_issue": "No", 
            "time_frame": "Monitoring will be from the last infusion of MSCs to the patient until 90 days after the last administration"
        }, 
        "source": "Red de Terapia Celular", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University Clinic of Navarra", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Haematology Service,University Hospital of Salamanca, M\u00aaConsuelo del Ca\u00f1izo Fern\u00e1ndez-Rold\u00e1n", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Virgen del Rocio University Hospital in Seville", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Spanish National Health System", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Red de Terapia Celular", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}